News and Trends 17 Nov 2022
VISEN growth hormone deficiency trial results announced
VISEN Pharmaceuticals has published detailed clinical data from its pivotal phase 3 study of lonapegsomatropin, a long-acting prodrug of unmodified somatropin being investigated as a once-weekly injection in children with…